Polygon Management Ltd.
13F Reported Value
ⓘ$635.1M
incl. option notional
Equity Holdings
ⓘ$614.3M
Option Notional
ⓘ$20.7M
$0 puts / $20.7M calls
Holdings
39
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Polygon Management Ltd. disclosed 39 positions worth $635.1M in its Form 13F-HR for Q2 2026 — $614.3M in common stock plus $20.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PATH (UiPath, Inc.) at 54.8% of the equity portfolio, followed by $KGEI and $AUTL. During the quarter the fund opened 10 new positions and exited 7 — including a new stake in $ALKT and a full exit from $PRAX. The portfolio is most concentrated in Technology (60.8% of disclosed assets). All figures are sourced directly from Polygon Management Ltd.’s Form 13F-HR filing with the SEC under CIK 1515070.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 69.9#240
Quality
$336.4M30,950,000 sh - —
Quality
$33.8M6,834,504 sh - —
Quality
$15.2M9,500,000 sh - 72.8
Quality
$14.6M1,000,000 sh - —
Quality
$13.5M286,990 sh - 65.4
Quality
$12.1M250,000 sh - 48.3
Quality
$11.4M2,200,000 sh - —
Quality
$11.2M203,543 sh - 38.6
Quality
$10.9M600,284 sh - 8.4
Quality
$10.8M290,441 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 UiPath, Inc.$PATH | 69.9#240 | $336.4M | 30,950,000 |
 Kolibri Global Energy Inc.$KGEI | — | $33.8M | 6,834,504 |
 Autolus Therapeutics plc$AUTL | — | $15.2M | 9,500,000 |
 Lyft, Inc.$LYFT | 72.8 | $14.6M | 1,000,000 |
 Definium Therapeutics, Inc.$DFTX | — | $13.5M | 286,990 |
 WORKIVA INC$WK | 65.4 | $12.1M | 250,000 |
 Sprinklr, Inc.$CXM | 48.3 | $11.4M | 2,200,000 |
 MBX Biosciences, Inc.$MBX | — | $11.2M | 203,543 |
 ALKAMI TECHNOLOGY, INC.$ALKT | 38.6 | $10.9M | 600,284 |
 Celldex Therapeutics, Inc.$CLDX | 8.4 | $10.8M | 290,441 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Polygon Management Ltd.'s 39 positions.
Showing top 10 of 39 holdings.
Sector Allocation
Technology
$373.3M
Healthcare
$185.9M
Energy
$33.8M
Industrials
$14.6M
Communication Services
$6.7M
Full Holdings — Polygon Management Ltd. (Q2 2026)
All 39 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PATH | UiPath, Inc. | $336.4M | 54.8% | +23% | 69.9 |
| 2 | $KGEI | Kolibri Global Energy Inc. | $33.8M | 5.5% | +0% | — |
| 3 | $AUTL | Autolus Therapeutics plc | $15.2M | 2.5% | +0% | — |
| 4 | $LYFT | Lyft, Inc. | $14.6M | 2.4% | +0% | 72.8 |
| 5 | $DFTX | Definium Therapeutics, Inc. | $13.5M | 2.2% | +43% | — |
| 6 | $WK | WORKIVA INC | $12.1M | 2.0% | +0% | 65.4 |
| 7 | $CXM | Sprinklr, Inc. | $11.4M | 1.9% | +0% | 48.3 |
| 8 | $MBX | MBX Biosciences, Inc. | $11.2M | 1.8% | +40% | — |
| 9 | $ALKT | ALKAMI TECHNOLOGY, INC. | $10.9M | 1.8% | NEW | 38.6 |
| 10 | $CLDX | Celldex Therapeutics, Inc. | $10.8M | 1.8% | -7% | 8.4 |
| 11 |  $RLAY | Relay Therapeutics, Inc. | $10.7M | 1.7% | +214% | 19.5 |
| 12 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.6M | 1.7% | +3% | 38.7 |
| 13 |  $PHVS | Pharvaris N.V. | $10.2M | 1.7% | +33% | — |
| 14 |  $ALKS | Alkermes plc. | $10.0M | 1.6% | +19% | — |
| 15 |  $IMVT | Immunovant, Inc. | $9.9M | 1.6% | +17% | — |
| 16 |  $AXSMCALL | Axsome Therapeutics, Inc. | $8.6M | — | +0% | 40.8 |
| 17 |  $SLN | Silence Therapeutics plc | $8.4M | 1.4% | +21% | — |
| 18 |  $DYN | Dyne Therapeutics, Inc. | $7.9M | 1.3% | +38% | — |
| 19 |  $IONS | IONIS PHARMACEUTICALS INC | $7.7M | 1.3% | +133% | 23.4 |
| 20 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $7.6M | 1.2% | +25% | 26.9 |
| 21 |  $HRMY | Harmony Biosciences Holdings, Inc. | $7.3M | 1.2% | +68% | 71.4 |
| 22 |  $KRYS | Krystal Biotech, Inc. | $7.3M | 1.2% | +0% | 79.2 |
| 23 |  $ANNX | Annexon, Inc. | $7.1M | 1.1% | -4% | — |
| 24 |  $CELC | Celcuity Inc. | $6.7M | 1.1% | NEW | — |
| 25 |  $WBD | Warner Bros. Discovery, Inc. | $6.7M | 1.1% | -73% | 41.4 |
| 26 |  $NKTR | NEKTAR THERAPEUTICS | $6.1M | 1.0% | -16% | 9.7 |
| 27 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $5.4M | 0.9% | -6% | 8.7 |
| 28 |  $ACAD | ACADIA PHARMACEUTICALS INC | $4.2M | 0.7% | +16% | 67.8 |
| 29 |  $RARECALL | Ultragenyx Pharmaceutical Inc. | $3.3M | — | NEW | 34.2 |
| 30 | $SLNCALL | Silence Therapeutics plc | $3.3M | — | NEW | — |
| 31 |  $CUE | Cue Biopharma, Inc. | $3.0M | 0.5% | NEW | 28.9 |
| 32 |  $SNOW | Snowflake Inc. | $2.5M | 0.4% | +0% | 54.9 |
| 33 |  $KPTICALL | Karyopharm Therapeutics Inc. | $2.4M | — | +401% | 15.1 |
| 34 |  $ACRS | Aclaris Therapeutics, Inc. | $2.1M | 0.3% | NEW | 12 |
| 35 | $AGIOCALL | AGIOS PHARMACEUTICALS, INC. | $1.9M | — | NEW | 26.9 |
| 36 |  $TECX | Tectonic Therapeutic, Inc. | $1.6M | 0.3% | +24% | — |
| 37 |  $GLUE | Monte Rosa Therapeutics, Inc. | $1.4M | 0.2% | NEW | 30.3 |
| 38 |  $TENXCALL | TENAX THERAPEUTICS, INC. | $1.1M | — | NEW | — |
| 39 | $AMLXCALL | Amylyx Pharmaceuticals, Inc. | $152,660 | — | NEW | 8.7 |
New Positions (10)
$ALKT ALKAMI TECHNOLOGY, INC.$10.9M$CELC Celcuity Inc.$6.7M$RARECALL Ultragenyx Pharmaceutical Inc.$3.3M$SLNCALL Silence Therapeutics plc$3.3M$CUE Cue Biopharma, Inc.$3.0M$ACRS Aclaris Therapeutics, Inc.$2.1M$AGIOCALL AGIOS PHARMACEUTICALS, INC.$1.9M$GLUE Monte Rosa Therapeutics, Inc.$1.4M$TENXCALL TENAX THERAPEUTICS, INC.$1.1M$AMLXCALL Amylyx Pharmaceuticals, Inc.$152,660
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Polygon Management Ltd. including:
Track Polygon Management Ltd.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Polygon Management Ltd. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Polygon Management Ltd.
13F Pro is an AI hedge fund tracker and stock research platform. For Polygon Management Ltd. (SEC CIK: 1515070), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Polygon Management Ltd.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.